Last reviewed · How we verify
Fada Remifentanilo
Remifentanil is a potent synthetic opioid agonist that binds to mu (μ) opioid receptors in the central nervous system to produce rapid analgesia and sedation.
Remifentanil is a potent synthetic opioid agonist that binds to mu (μ) opioid receptors in the central nervous system to produce rapid analgesia and sedation. Used for Intravenous analgesia and sedation during general anesthesia, Analgesia in mechanically ventilated patients in intensive care settings.
At a glance
| Generic name | Fada Remifentanilo |
|---|---|
| Sponsor | Fundación Universitaria de Ciencias de la Salud |
| Drug class | Opioid agonist |
| Target | Mu (μ) opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia and Pain Management |
| Phase | FDA-approved |
Mechanism of action
Remifentanil activates mu opioid receptors, which are G-protein coupled receptors that modulate pain perception and consciousness. It is characterized by rapid onset and offset due to metabolism by non-specific plasma and tissue esterases, making it suitable for short procedures and intravenous anesthesia. The drug crosses the blood-brain barrier quickly to produce potent analgesic and sedative effects.
Approved indications
- Intravenous analgesia and sedation during general anesthesia
- Analgesia in mechanically ventilated patients in intensive care settings
Common side effects
- Respiratory depression
- Hypotension
- Bradycardia
- Muscle rigidity
- Nausea and vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |